Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Michael J. Mitchell

TitleInstructor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-EM MED Clinical
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-EM MED Clinical


    Collapse Research 
    Collapse research activities and funding
    R01HD115877     (MITCHELL, MICHAEL J)Aug 12, 2024 - Jul 31, 2029
    NIH
    mRNA lipid nanoparticles for pre-eclampsia
    Role: Principal Investigator
    DP2TR002776     (MITCHELL, MICHAEL J)Sep 20, 2018 - May 31, 2023
    NIH
    A data-driven drug delivery (4D) platform for probing and treating the chemoresistant bone marrow microenvironment
    Role: Principal Investigator
    F32CA200351     (MITCHELL, MICHAEL J)Aug 13, 2015 - Aug 12, 2018
    NIH
    Polymeric Nanoparticles for siRNA Delivery to Bone Marrow Endothelium to Disrupt Tumor Cell Adhesion and Bone Metastasis Formation In Vivo
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Haley RM, Padilla MS, El-Mayta RD, Joseph RA, Weber JA, Figueroa-Espada CG, Mukalel AJ, Ricciardi AS, Palanki R, Geisler HC, Jester MT, Davidson BL, Mitchell MJ. Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical Targets. ACS Nano. 2025 04 15; 19(14):13790-13804. PMID: 40183470.
      View in: PubMed
    2. Hwang YH, Shepherd SJ, Kim D, Mukalel AJ, Mitchell MJ, Issadore DA, Lee D. Robust, Scalable Microfluidic Manufacturing of RNA-Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating. ACS Nano. 2025 01 14; 19(1):1090-1102. PMID: 39700475.
      View in: PubMed
    3. Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari SA. Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers. ACS Nano. 2024 12 24; 18(51):34425-34463. PMID: 39666006.
      View in: PubMed
    4. Hamilton AG, Swingle KL, Thatte AS, Mukalel AJ, Safford HC, Billingsley MM, El-Mayta RD, Han X, Nachod BE, Joseph RA, Metzloff AE, Mitchell MJ. High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route. ACS Nano. 2024 06 25; 18(25):16151-16165. PMID: 38861479.
      View in: PubMed
    5. Anchordoquy T, Artzi N, Balyasnikova IV, Barenholz Y, La-Beck NM, Brenner JS, Chan WCW, Decuzzi P, Exner AA, Gabizon A, Godin B, Lai SK, Lammers T, Mitchell MJ, Moghimi SM, Muzykantov VR, Peer D, Nguyen J, Popovtzer R, Ricco M, Serkova NJ, Singh R, Schroeder A, Schwendeman AA, Straehla JP, Teesalu T, Tilden S, Simberg D. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions. ACS Nano. 2024 06 04; 18(22):13983-13999. PMID: 38767983.
      View in: PubMed
    6. Palanki R, Bose SK, Dave A, White BM, Berkowitz C, Luks V, Yaqoob F, Han E, Swingle KL, Menon P, Hodgson E, Biswas A, Billingsley MM, Li L, Yiping F, Carpenter M, Trokhan A, Yeo J, Johana N, Wan TY, Alameh MG, Bennett FC, Storm PB, Jain R, Chan J, Weissman D, Mitchell MJ, Peranteau WH. Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease. ACS Nano. 2023 07 25; 17(14):13594-13610. PMID: 37458484.
      View in: PubMed
    7. Nong J, Glassman PM, Myerson JW, Zuluaga-Ramirez V, Rodriguez-Garcia A, Mukalel A, Omo-Lamai S, Walsh LR, Zamora ME, Gong X, Wang Z, Bhamidipati K, Kiseleva RY, Villa CH, Greineder CF, Kasner SE, Weissman D, Mitchell MJ, Muro S, Persidsky Y, Brenner JS, Muzykantov VR, Marcos-Contreras OA. Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured Brain. ACS Nano. 2023 07 25; 17(14):13121-13136. PMID: 37432926.
      View in: PubMed
    8. Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, Peer D, Tao W. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol. 2022 10; 17(10):1027-1037. PMID: 35982317.
      View in: PubMed
    9. Parhiz H, Brenner JS, Patel PN, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora ME, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson JW, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov VR. Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE). J Control Release. 2022 04; 344:50-61. PMID: 34953981.
      View in: PubMed
    10. Guimarães PPG, Gaglione S, Sewastianik T, Carrasco RD, Langer R, Mitchell MJ. Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. ACS Nano. 2018 02 27; 12(2):912-931. PMID: 29378114.
      View in: PubMed
    Mitchell's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (47) concept(s)
    _
    Co-Authors Expand Description
    See all (3) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)